Progress in determining response to treatment in gastrointestinal stromal tumor

References

• Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer. 2005;103(4):821–829.
   PubMed Web of Science ®Google Scholar
• Ma GL, Murphy JD, Martinez ME, et al. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev. 2015;24(1):298–302.
   PubMed Web of Science ®Google Scholar
• Li GZ, Raut CP. Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies. Onco Targets Ther. 2019;12:5123–5133.
   PubMed Web of Science ®Google Scholar
• Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol. 1999;23(4):377–389.
   PubMed Web of Science ®Google Scholar
• Novelli M, Rossi S, Rodriguez-Justo M, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology. 2010;57(2):259–270.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Virolainen M, Maarit Sarlomo R. Gastrointestinal stromal tumors – value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol. 1995;19(2):207–216.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol. 2000;13(10):1134–1142.
   PubMed Web of Science ®Google Scholar
• Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11(8):728–734.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Wang ZF, Sarlomo-Rikala M, et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011;35(11):1712–1721.
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–580.
   PubMed Web of Science ®Google Scholar
• Maleddu A, Pantaleo MA, Nannini M, et al. The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting. J Transl Med. 2011;9(1):75.
   PubMedGoogle Scholar
• Rubin BP, Heinrich MC. Genotyping and immunohistochemistry of gastrointestinal stromal tumors: an update. Semin Diagn Pathol. 2015;32(5):392–399.
   PubMed Web of Science ®Google Scholar
• Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol. 2006;23(2):91–102.
   PubMed Web of Science ®Google Scholar
• Nannini M, Biasco G, Astolfi A, et al. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). J Med Genet. 2013;50(10):653–661.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Lennartsson J. Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. Cold Spring Harb Perspect Biol. 2013;5(8):a009100.
   PubMed Web of Science ®Google Scholar
• von Mehren M, Joensuu H. Gastrointestinal stromal tumors. J Clin Oncol. 2018;36(2):136–143.
   PubMed Web of Science ®Google Scholar
• Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357–5364.
   PubMed Web of Science ®Google Scholar
• Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res. 2009;15(24):7510–7518.
   PubMed Web of Science ®Google Scholar
• Oppelt PJ, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J Gastrointest Oncol. 2017;8(3):466–473.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Wiemer E, Seynaeve C, et al. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist. 2007;12(6):719–726.
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–480.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620–625.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26(33):5360–5367.
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–1338.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Jones RL, Mehren M, et al. Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA exon 18 gastrointestinal stromal tumors (GIST). J clin oncol. 2019;37(15_suppl):11022.
   Web of Science ®Google Scholar
• Schneider-Stock R. BLU-285-the breakthrough in treatment of patients with aggressive systemic mastocytosis and gastrointestinal stromal tumor. Ann Transl Med. 2018;6(11):232.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Blay JY, Comandone A, et al. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. Br J Cancer. 2017;117(9):1278–1285.
   PubMed Web of Science ®Google Scholar
• Montemurro M, Cioffi A, Domont J, et al. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: a multicenter, 2-stage phase 2 trial (Swiss Group for clinical cancer research 56/07). Cancer. 2018;124(7):1449–1454.
   PubMed Web of Science ®Google Scholar
• Mir O, Cropet C, Toulmonde M, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol. 2016;17(5):632–641.
   PubMed Web of Science ®Google Scholar
• Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs. 2012;30(6):2377–2383.
   PubMed Web of Science ®Google Scholar
• Schuetze SM, Bolejack V, Thomas DG, et al. Association of dasatinib with progression-free survival among patients with advanced gastrointestinal stromal tumors resistant to imatinib. JAMA Oncol. 2018;4(6):814–820.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, von Mehren M, Demetri GD et al. A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: initial report. Ed.^(Eds). American Society of Clinical Oncology; 2014.
   Google Scholar
• Reichardt P, Blay JY, Gelderblom H, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol. 2012;23(7):1680–1687.
   PubMed Web of Science ®Google Scholar
• Gebreyohannes YK, Burton EA, Wozniak A, et al. PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors. Clin Exp Med. 2019;19(2):201–210.
   PubMed Web of Science ®Google Scholar
• Rosenbaum E, Kelly C, D’Angelo SP, et al. A phase I study of binimetinib (MEK162) combined with pexidartinib (PLX3397) in patients with advanced gastrointestinal stromal tumor. Oncologist. 2019;24(10):1309.
   Web of Science ®Google Scholar
• Judson I, Scurr M, Gardner K, et al. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clin Cancer Res. 2014;20(13):3603–3612.
   PubMed Web of Science ®Google Scholar
• Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–1104.
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013;258(3):422–429.
   PubMed Web of Science ®Google Scholar
• Eisenberg BL. The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors. Am J Clin Oncol. 2013;36(1):89–90.
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459–465.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29(1):52–68.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130(10):1466–1478.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Hall KS, et al. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 2014;120(15):2325–2333.
   PubMed Web of Science ®Google Scholar
• Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10(11):1045–1052.
   PubMed Web of Science ®Google Scholar
• Rossi S, Gasparotto D, Miceli R, et al. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study. Am J Surg Pathol. 2015;39(7):922–930.
   PubMed Web of Science ®Google Scholar
• Liu X, Chu KM. Molecular biomarkers for prognosis of gastrointestinal stromal tumor. Clin Transl Oncol. 2019;21(2):145–151.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Patterson J, Beadling C, et al. Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). Clin Sarcoma Res. 2019;9(1):3.
   PubMedGoogle Scholar
• Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist. 2008;13(Suppl 2):4–7.
   PubMed Web of Science ®Google Scholar
• Tirkes T, Hollar MA, Tann M, et al. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics. 2013;33(5):1323–1341.
   PubMed Web of Science ®Google Scholar
• Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122s–150s.
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou-Strauss A, Ronellenfitsch U, Cheng C, et al. Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. Clin Transl Imaging. 2017;5(3):183–197.
   PubMed Web of Science ®Google Scholar
• Tirumani SH, Shinagare AB, Jagannathan JP, et al. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection. Eur J Surg Oncol. 2014;40(4):420–428.
   PubMed Web of Science ®Google Scholar
• Schiavon G, Ruggiero A, Bekers DJ, et al. The effect of baseline morphology and its change during treatment on the accuracy of response evaluation criteria in solid tumours in assessment of liver metastases. Eur J Cancer. 2014;50(5):972–980.
   PubMed Web of Science ®Google Scholar
• Shinagare AB, Jagannathan JP, Kurra V, et al. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. Eur J Cancer. 2014;50(5):981–986.
   PubMed Web of Science ®Google Scholar
• Dudeck O, Zeile M, Reichardt P, et al. Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2011;22(8):1828–1833.
   PubMed Web of Science ®Google Scholar
• Betz M, Kopp HG, Spira D, et al. The benefit of using CT-perfusion imaging for reliable response monitoring in patients with gastrointestinal stromal tumor (GIST) undergoing treatment with novel targeted agents. Acta Radiol. 2013;54(7):711–721.
   PubMed Web of Science ®Google Scholar
• Stroobants S, Goeminne J, Seegers M, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39(14):2012–2020.
   PubMed Web of Science ®Google Scholar
• Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32(2):153–162.
   PubMed Web of Science ®Google Scholar
• Prior JO, Montemurro M, Orcurto MV, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009;27(3):439–445.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Bui BN, et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer. 2010;46(8):1344–1351.
   PubMed Web of Science ®Google Scholar
• Kang YK, Yoo C, Ryoo BY, et al. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br J Cancer. 2013;109(9):2309–2315.
   PubMed Web of Science ®Google Scholar
• Hassanzadeh-Rad A, Yousefifard M, Katal S, et al. The value of (18) F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):929–935.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83.
   PubMed Web of Science ®Google Scholar
• Wu CE, Tzen CY, Wang SY, et al. Clinical diagnosis of gastrointestinal stromal tumor (GIST): from the molecular genetic point of view. Cancers (Basel). 2019;11(5):679.
   Web of Science ®Google Scholar
• Marrari A, Wagner AJ, Hornick JL. Predictors of response to targeted therapies for gastrointestinal stromal tumors. Arch Pathol Lab Med. 2012;136(5):483–489.
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Viale A, Sarran L, et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res. 2004;10(10):3282–3290.
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11(11):4182–4190.
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group Study. J Clin Oncol. 2005;23(24):5795–5804.
   PubMed Web of Science ®Google Scholar
• Wang WL, Conley A, Reynoso D, et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011;67(Suppl 1):S15–24.
   PubMedGoogle Scholar
• Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial. JAMA Oncol. 2017;3(5):602–609.
   PubMed Web of Science ®Google Scholar
• Guo T, Hajdu M, Agaram NP, et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res. 2009;15(22):6862–6870.
   PubMed Web of Science ®Google Scholar
• Szucs Z, Thway K, Fisher C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017;13(1):93–107.
   PubMed Web of Science ®Google Scholar
• Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer. 2008;44(4):501–509.
   PubMed Web of Science ®Google Scholar
• Cassier PA, Fumagalli E, Rutkowski P, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012;18(16):4458–4464.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Kindler H, Gelderblom H, et al. A phase II study of a human anti-PDGFRalpha monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Ann Oncol. 2017;28(3):541–546.
   PubMed Web of Science ®Google Scholar
• Wang YM, Gu ML, Ji F. Succinate dehydrogenase-deficient gastrointestinal stromal tumors. World J Gastroenterol. 2015;21(8):2303–2314.
   PubMed Web of Science ®Google Scholar
• Ihle MA, Fassunke J, Konig K, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer. 2014;14(1):13.
   PubMedGoogle Scholar
• Boonstra PA, Ter Elst A, Tibbesma M, et al. A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. Oncotarget. 2018;9(17):13870–13883.
   PubMedGoogle Scholar
• Ilie M, Hofman P. Pros: can tissue biopsy be replaced by liquid biopsy? Transl Lung Cancer Res. 2016;5(4):420–423.
   PubMed Web of Science ®Google Scholar
• Kang G, Sohn BS, Pyo JS, et al. Detecting primary KIT mutations in presurgical plasma of patients with gastrointestinal stromal tumor. Mol Diagn Ther. 2016;20(4):347–351.
   PubMed Web of Science ®Google Scholar
• Namlos HM, Boye K, Mishkin SJ, et al. Noninvasive detection of ctDNA reveals intratumor heterogeneity and is associated with tumor burden in gastrointestinal stromal tumor. Mol Cancer Ther. 2018;17(11):2473–2480.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(28):3375–3382.
   PubMed Web of Science ®Google Scholar
• Scholer LV, Reinert T, Orntoft MW, et al. Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2017;23(18):5437–5445.
   PubMed Web of Science ®Google Scholar
• Arshad J, Roberts A, Nagy RJ, et al. Utility of circulating tumor DNA (ctDNA) in the management of patients with gastrointestinal stromal tumor (GIST): analysis of 152 patients. J clin oncol. 2018;36(15_suppl):11539.
   Web of Science ®Google Scholar
• Arshad J, Roberts A, Cotta JA, et al. Identification of genomic alterations by circulating tumor DNA in leiomyosarcoma: a molecular analysis of 73 patients. J clin oncol. 2019;37(15_suppl):11044.
   Web of Science ®Google Scholar
• Barris DM, Weiner SB, Dubin RA, et al. Detection of circulating tumor DNA in patients with osteosarcoma. Oncotarget. 2018;9(16):12695–12704.
   PubMedGoogle Scholar
• Xu H, Chen L, Shao Y, et al. Clinical application of circulating tumor DNA in the genetic analysis of patients with advanced GIST. Mol Cancer Ther. 2018;17(1):290–296.
   PubMed Web of Science ®Google Scholar
• Florou V, Ramdial JL, Trent JC. Use of tyrosine kinase inhibitors in patients with GI stromal tumor who are pregnant or considering pregnancy: driver mutations and circulating tumor DNA. J Clin Oncol. 2018;36(25):2659–2660.
   PubMed Web of Science ®Google Scholar
• Arshad J, Wilky BA, Roberts A, et al. Utility of circulaitng tumor DNA (ctDNA) in the managment of gatrointestinal stromal tumor (GIST); analysis of 184 patients. In: Ed.^, editor. CTOS, 2018. Rome, Italy; 2018.
   Google Scholar
• Janku F, Zhang S, Waters J, et al. Development and validation of an ultradeep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2017;23(18):5648–5656.
   PubMed Web of Science ®Google Scholar
• Arshad J, Roberts A, Ahmed J, et al. Utility of circulating tumor DNA in the management of patients with GI stromal tumor: analysis of 243 patients. JCO Precis Oncol. 2020;(4):66–73.
   Google Scholar
• Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883–1889.
   PubMed Web of Science ®Google Scholar